Europeanhhm

Study Demonstrates Delphinus's SoftVue Ultrasound Tomography Enhances Breast Cancer Screening with Mammography in Women with Dense Breasts

Monday, July 01, 2024

Delphinus Medical Technologies has announced a new study comparing the effectiveness of mammography alone versus mammography combined with their SoftVue™ Breast Ultrasound Tomography (UST) in women with dense breasts.

Published in the journal Radiology, the study, “Comparison of Mammography and Mammography with Supplemental Whole-Breast US Tomography for Cancer Detection in Patients with Dense Breasts,” reveals that the combination significantly enhances cancer detection.

Section Chief of Breast Imaging and Clinical Professor of Radiology and Surgery at the University of Southern California, Keck School of Medicine, highlighted the study's importance:

“Findings show increased cancer detection and improved BIRADS 3 specificity with SoftVue UST used alongside mammography.

This helps radiologists better differentiate benign masses, reducing the need for short-term follow-ups.”

The study involved 140 cases reviewed by 32 qualified radiologists from various practices. Each radiologist independently evaluated mammograms and assigned BI-RADS scores, then reassessed the same cases with the addition of UST.

Key results from the study include:

  • A statistically significant improvement in breast cancer detection when combining SoftVue UST with mammography.
  • A 25% increase in sensitivity for detecting BI-RADS 4 or higher lesions.
  • An 8% improvement in specificity for BI-RADS 3 lesions.

Medical Director of Delphinus Medical Technologies, stated, “SoftVue offers a vital solution for dense breast screening, increasing cancer detection and reducing unnecessary follow-ups.

This means quicker referrals for biopsies in cancer cases and reassurance for women without cancer.”

Mammography reduces mortality by 41% in women with non-dense breasts but only by 13% in women with dense breasts. To address this, federal breast density notifications will be mandated from September 2024, highlighting the need for supplemental screening.

SoftVue UST, when paired with mammography, provides a thorough annual screening solution for women with dense breasts and is the only FDA-approved ultrasound-based breast imaging system for same-day screening.

 

 

 

 

Source: businesswire.com

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress